

Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD) - Forecasts to 2021

<https://marketpublishers.com/r/P7D157EA2BEEN.html>

Date: February 2017

Pages: 153

Price: US\$ 5,650.00 (Single User License)

ID: P7D157EA2BEEN

Abstracts

The global pulmonary drug delivery market is projected to reach USD 52.37 billion by 2021 from USD 36.10 billion in 2016, at a CAGR of 6.5% during the forecast period. Increasing preference of pulmonary route as an alternate route of drug delivery, rising focus on the development of smart/digital inhalers and increasing incidence of respiratory diseases such as COPD, asthma, and cystic fibrosis is expected to drive the market growth during the forecast period. However, emerging markets and growth in online marketing channel offers opportunities for the market.

The pulmonary drug delivery market is segmented based on formulations, canister type, applications, end users, and regions.

Based on canister type, the market is segmented into plain canister and coated canister. The coated canister segment is expected to witness the highest growth during the forecast period due to various advantages such as robust profile for filling, avoiding crimping, and withstanding the pressure associated with the type of propellant (HFAs or CFCs), minimizing formulation and canister interactions and avoids deposition of HFA on the canister surface.

Based on applications, the market is segmented into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other applications (cardiovascular

disease, diabetes, respiratory therapy, and treatment of patients on ventilators). The asthma segment is expected to witness the highest growth during the forecast period due to increasing prevalence of asthma across the globe.

Based on the end user, the market is segmented into hospitals & clinics and homecare settings. Homecare settings is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to technological advancements in pulmonary drug delivery devices that enable their use in the home care settings. Digital inhalers allow patients to maintain medical records and dosage of the drug administered; this also enable patients to share this record with physicians.

Asian market is expected to register the highest CAGR during the forecast period due to the rapidly growing aging population, increasing adoption of an unhealthy lifestyle, increasing urbanization, exposure to smoke & chemicals, and the subsequent increase in the prevalence of COPD in the region. Presently, North America is expected to dominate the market. This is due to increasing technological developments, increasing prevalence of chronic respiratory and supportive reimbursement policies in the form of Medicare and Medicaid

The key players in the pulmonary drug delivery market focus on various organic and inorganic growth strategies such as agreements, collaborations, expansions, product launches & approvals, and partnerships.

The key players in this market are Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline (U.K.), Boehringer Ingelheim GmbH (Germany), 3M (U.S.), AstraZeneca plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Omron Corporation (Japan), and Sunovion Pharmaceuticals Inc. (U.S.).

Apart from the comprehensive geographical analysis, product analysis, and market sizing the report also provides a competitive landscape that covers the growth strategies adopted by industry players in the last three years. In addition, the company profiles comprise basic views on the key players and their product portfolios, developments, and strategies adopted. The abovementioned market research data, current market sizes, and forecast of future trends will help key players and new entrants make informed decisions regarding product offerings, geographical focus, change in strategic approach, and R&D investments for innovations in products and technologies, and levels of output to remain successful.

Research Coverage:

Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Ty...

The report defines, describes, and forecasts the pulmonary drug delivery market on the basis of formulations, canister type, application, end user, and regions. It provides detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, challenges). The study tracks and analyzes competitive developments such as acquisitions, product developments, and expansions in the pulmonary drug delivery market across four main regions, namely, North America, Asia, Europe, and the Rest of the World (RoW).

Reasons to buy the report:

The report on “Pulmonary Drug Delivery” provides quantitative information for clients seeking market size information on various segments of the pulmonary drug delivery market.

This report also provides access to the quantitative data on pulmonary drug delivery market. This report covers –

- Current and forecast assessment of the global pulmonary drug delivery market

- Country-wise assessment of each of the segments

- Global market share analysis of major segments of the pulmonary drug delivery market

- Adoption trends of pulmonary drug delivery in major geographic segments

- Five-year coverage of strategic developments of top players in the pulmonary drug delivery market

- Product portfolio mapping of leading players in the pulmonary drug delivery market

Contents

1 INTRODUCTION

- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
 - 1.3.1 MARKETS COVERED
 - 1.3.2 YEARS CONSIDERED FOR THE STUDY
- 1.4 CURRENCY
- 1.5 LIMITATIONS
- 1.6 MARKET STAKEHOLDERS

2 RESEARCH METHODOLOGY

- 2.1 MARKET SIZE ESTIMATION
- 2.2 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.3 KEY DATA FROM SECONDARY SOURCES
- 2.4 KEY DATA FROM PRIMARY SOURCES
- 2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

- 4.1 PULMONARY DRUG DELIVERY: MARKET OVERVIEW
- 4.2 GEOGRAPHIC ANALYSIS: PULMONARY DRUG DELIVERY MARKET, BY APPLICATION (2016)
- 4.3 PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE (2016 VS. 2021)
- 4.4 PULMONARY NEBULIZERS MARKET, BY TYPE (2016–2021)
- 4.5 GEOGRAPHIC SNAPSHOT: PULMONARY DRUG DELIVERY MARKET

5 MARKET OVERVIEW

- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
 - 5.2.1 MARKET DRIVERS
 - 5.2.1.1 Increasing preference for pulmonary drug delivery as an alternate route of drug delivery

5.2.1.2 Increasing focus on the development of smart/digital inhalers

5.2.1.3 Increasing incidence of respiratory diseases

5.2.2 MARKET RESTRAINTS

5.2.2.1 Regulatory issues

5.2.2.2 Pricing pressure

5.2.3 MARKET OPPORTUNITIES

5.2.3.1 Emerging markets

5.2.3.2 Growth in online marketing channels

5.2.4 MARKET CHALLENGES

5.2.4.1 Issues with the stability of drugs

5.2.4.2 Deposition of aerosolized particles

6 PULMONARY DRUG DELIVERY MARKET, BY FORMULATION

6.1 INTRODUCTION

6.2 TYPE

6.2.1 SUSPENSION AEROSOLS

6.2.2 SOLUTION AEROSOLS

6.2.3 DRY POWDER FORMULATIONS

6.3 DEVICE TYPE

6.3.1 METERED DOSE INHALERS (MDIS)

6.3.2 DRY POWDER INHALERS (DPIS)

6.3.3 NEBULIZERS

6.3.3.1 Jet Nebulizers

6.3.3.2 Ultrasonic Nebulizers

6.3.3.3 Soft mist nebulizers

7 PULMONARY DRUG DELIVERY MARKET, BY CANISTER TYPE

7.1 INTRODUCTION

7.2 PLAIN CANISTERS

7.3 COATED CANISTER

8 PULMONARY DRUG DELIVERY MARKET, BY APPLICATION

8.1 INTRODUCTION

8.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE

8.3 ASTHMA

8.4 CYSTIC FIBROSIS

8.5 OTHER APPLICATIONS

9 PULMONARY DRUG DELIVERY MARKET, BY END USER

9.1 INTRODUCTION

9.2 HOSPITALS & CLINICS

9.3 HOME CARE SETTINGS

10 PULMONARY DRUG DELIVERY MARKET, BY REGION

10.1 INTRODUCTION

10.2 NORTH AMERICA

10.2.1 U.S.

10.2.2 CANADA

10.3 EUROPE

10.3.1 GERMANY

10.3.2 U.K.

10.3.3 FRANCE

10.3.4 REST OF EUROPE

10.4 ASIA

10.4.1 CHINA

10.4.2 INDIA

10.4.3 JAPAN

10.4.4 REST OF ASIA

10.5 REST OF THE WORLD

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW

11.2 MARKET RANK ANALYSIS

11.3 COMPETITIVE SITUATIONS AND TRENDS

11.3.1 COLLABORATIONS

11.3.2 PRODUCT LAUNCHES AND REGULATORY APPROVALS

11.3.3 ACQUISITIONS

11.3.4 EXPANSIONS

12 COMPANY PROFILES

(Overview, Products and Services, Financials, Strategy & Development)*

Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Ty...

12.1 INTRODUCTION**12.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.****12.3 3M****12.4 GLAXOSMITHKLINE PLC****12.5 ASTRAZENECA PLC****12.6 BOEHRINGER INGELHEIM****12.7 MERCK & CO., INC.****12.8 NOVARTIS AG****12.9 OMRON CORPORATION****12.10 SUNOVION PHARMACEUTICALS INC. (A PART OF SUMITOMO DAINIPPON PHARMA CO., LTD.)****12.11 CIPLA INC.**

*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

13 APPENDIX**13.1 INSIGHTS FROM INDUSTRY EXPERTS****13.2 DISCUSSION GUIDE****13.3 KNOWLEDGE STORE: MARKETSDANDMARKETS' SUBSCRIPTION PORTAL****13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE****13.5 AVAILABLE CUSTOMIZATIONS****13.6 RELATED REPORTS****13.7 AUTHOR DETAILS**

List Of Tables

LIST OF TABLES

Table 1 COMPANIES DEVELOPING SMART/DIGITAL INHALER TECHNOLOGIES

Table 2 PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)

Table 3 SUSPENSION AEROSOLS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 4 SOLUTION AEROSOLS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 5 DRY POWDER FORMULATIONS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 6 PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE , 2014–2021 (USD MILLION)

Table 7 METERED DOSE INHALERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 8 DRY DOSE INHALERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 9 NEBULIZERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)

Table 10 NEBULIZERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 11 JET NEBULIZERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 12 ULTRASONIC NEBULIZERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 13 SOFT MIST NEBULIZERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 14 PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION)

Table 15 PLAIN CANISTERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 16 COATED CANISTERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 17 PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)

Table 18 PULMONARY DRUG DELIVERY MARKET SIZE FOR COPD, BY REGION, 2014–2021 (USD MILLION)

Table 19 PULMONARY DRUG DELIVERY MARKET SIZE FOR ASTHMA, BY REGION, 2014–2021 (USD MILLION)

Table 20 PULMONARY DRUG DELIVERY MARKET SIZE FOR CYSTIC FIBROSIS, BY REGION, 2014–2021 (USD MILLION)

Table 21 PULMONARY DRUG DELIVERY MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2014–2021 (USD MILLION)

Table 22 PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 23 PULMONARY DRUG DELIVERY MARKET SIZE FOR HOSPITALS & CLINICS, BY REGION, 2014–2021 (USD MILLION)

Table 24 PULMONARY DRUG DELIVERY MARKET SIZE FOR HOME CARE SETTINGS, BY REGION, 2014–2021 (USD MILLION)

Table 25 GLOBAL PULMONARY DRUG DELIVERY MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 26 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)

Table 27 NORTH AMERICA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)

Table 28 NORTH AMERICA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014–2021 (USD MILLION)

Table 29 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION)

Table 30 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 31 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)

Table 32 U.S.: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)

Table 33 U.S.: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014–2021 (USD MILLION)

Table 34 U.S.: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION)

Table 35 U.S.: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 36 U.S.: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)

Table 37 CANADA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)

Table 38 CANADA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014–2021 (USD MILLION)

Table 39 CANADA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION)

Table 40 CANADA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER,

2014–2021 (USD MILLION)

Table 41 CANADA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)

Table 42 EUROPE: PULMONARY DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)

Table 43 EUROPE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)

Table 44 EUROPE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014–2021 (USD MILLION)

Table 45 EUROPE: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION)

Table 46 EUROPE: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 47 EUROPE: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)

Table 48 GERMANY: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)

Table 49 GERMANY: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014–2021 (USD MILLION)

Table 50 GERMANY: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION)

Table 51 GERMANY: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 52 GERMANY: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)

Table 53 U.K.: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)

Table 54 U.K.: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014–2021 (USD MILLION)

Table 55 U.K.: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION)

Table 56 U.K.: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 57 U.K.: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)

Table 58 FRANCE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)

Table 59 FRANCE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014–2021 (USD MILLION)

Table 60 FRANCE: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION)

Table 61 FRANCE: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 62 FRANCE: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)

Table 63 ROE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)

Table 64 ROE: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014–2021 (USD MILLION)

Table 65 ROE: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION)

Table 66 ROE: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 67 ROE: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)

Table 68 ASIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)

Table 69 ASIA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)

Table 70 ASIA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014–2021 (USD MILLION)

Table 71 ASIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION)

Table 72 ASIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 73 ASIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)

Table 74 CHINA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)

Table 75 CHINA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014–2021 (USD MILLION)

Table 76 CHINA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION)

Table 77 CHINA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 78 CHINA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)

Table 79 INDIA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE,

BY TYPE, 2014–2021 (USD MILLION)

Table 80 INDIA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014–2021 (USD MILLION)

Table 81 INDIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION)

Table 82 INDIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 83 INDIA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)

Table 84 JAPAN: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)

Table 85 JAPAN: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014–2021 (USD MILLION)

Table 86 JAPAN: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION)

Table 87 JAPAN: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 88 JAPAN: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)

Table 89 ROA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)

Table 90 ROA: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014–2021 (USD MILLION)

Table 91 ROA: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION)

Table 92 ROA: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 93 ROA: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)

Table 94 ROW: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)

Table 95 ROW: PULMONARY DRUG DELIVERY FORMULATIONS MARKET SIZE, BY DEVICE TYPE, 2014–2021 (USD MILLION)

Table 96 ROW: PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2014–2021 (USD MILLION)

Table 97 ROW: PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 98 ROW: PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)

Table 99 MARKET RANKING OF THE KEY PLAYERS IN THE PULMONARY DRUG DELIVERY MARKET (2015)

Table 100 COLLABORATIONS, 2014–2016

Table 101 PRODUCT LAUNCHES AND REGULATORY APPROVALS, 2014–2016

Table 102 ACQUISITIONS, 2014–2016

Table 103 EXPANSIONS, 2014–2016

Table 104 EXCHANGE RATE (UTILIZED FOR THE CONVERSION OF GBP TO USD)

List Of Figures

LIST OF FIGURES

Figure 1 RESEARCH DESIGN

Figure 2 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH

Figure 3 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH

Figure 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

Figure 5 DATA TRIANGULATION METHODOLOGY

Figure 6 GLOBAL PULMONARY DRUG DELIVERY MARKET SIZE, BY DEVICE TYPE, 2016 VS. 2021

Figure 7 GLOBAL PULMONARY DRUG DELIVERY MARKET SIZE, BY APPLICATION, 2016 VS. 2021

Figure 8 GLOBAL PULMONARY DRUG DELIVERY MARKET SIZE, BY CANISTER TYPE, 2016 VS. 2021

Figure 9 GLOBAL PULMONARY DRUG DELIVERY MARKET SIZE, BY END USER, 2016 VS. 2021

Figure 10 GEOGRAPHICAL SNAPSHOT OF THE PULMONARY DRUG DELIVERY MARKET

Figure 11 INCREASING INCIDENCE OF RESPIRATORY DISEASES IS A KEY MARKET DRIVER FOR PULMONARY DRUG DELIVERY

Figure 12 ASTHMA FORMS THE LARGEST APPLICATION SEGMENT IN THE PULMONARY DRUG DELIVERY MARKET

Figure 13 METERED-DOSE INHALERS TO COMMAND THE LARGEST MARKET SHARE IN 2016

Figure 14 JET NEBULIZERS TO DOMINATE THE PULMONARY NEBULIZERS MARKET IN 2016

Figure 15 CHINA TO REGISTER HIGHEST GROWTH RATE DURING THE FORECAST PERIOD

Figure 16 PULMONARY DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

Figure 17 U.K.: ESTIMATED NUMBER OF PEOPLE DIAGNOSED WITH ASTHMA (2004–2012)

Figure 18 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET SNAPSHOT

Figure 19 EUROPE: PULMONARY DRUG DELIVERY MARKET SNAPSHOT

Figure 20 ASIA: PULMONARY DRUG DELIVERY MARKET SNAPSHOT

Figure 21 KEY DEVELOPMENTS IN THE PULMONARY DRUG DELIVERY MARKET, 2014–2016

Figure 22 BATTLE FOR MARKET SHARE: COLLABORATIONS ACCOUNTED FOR THE LARGEST SHARE OF THE TOTAL DEVELOPMENTS DURING 2014 TO 2016

Figure 23 GEOGRAPHIC REVENUE MIX FOR THE TOP 5 PLAYERS IN THE PULMONARY DRUG DELIVERY MARKET

Figure 24 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2015)

Figure 25 3M: COMPANY SNAPSHOT (2015)

Figure 26 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2015)

Figure 27 ASTRAZENECA PLC: COMPANY SNAPSHOT (2015)

Figure 28 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2015)

Figure 29 MERCK & CO., INC.: COMPANY SNAPSHOT (2015)

Figure 30 NOVARTIS AG: COMPANY SNAPSHOT (2015)

Figure 31 OMRON CORPORATION: COMPANY SNAPSHOT (2015)

Figure 32 SUMITOMO DAINIPPON PHARMA CO., LTD.: COMPANY SNAPSHOT (2015)

Figure 33 CIPLA INC.: COMPANY SNAPSHOT (2016)

I would like to order

Product name: Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD) - Forecasts to 2021

Product link: <https://marketpublishers.com/r/P7D157EA2BEEN.html>

Price: US\$ 5,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P7D157EA2BEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970